Key Highlights
- Amgen finished among the decliners on the Dow Jones Industrial Average on Friday, with no company-specific news found, as health care became the only S&P 500 sector to fall.
- Fellow Dow names Johnson & Johnson and Merck also finished lower, while Nasdaq-100 decliners included Alnylam Pharmaceuticals, Gilead Sciences, Intuitive Surgical and DexCom, and drug distributors Cardinal Health, McKesson and Cencora fell in the S&P 500.
- Health care was one of the few sectors still hiring in the September jobs report, adding 17,000 positions, even as the weak overall report cut odds of another Federal Reserve rate hike.
- Moderna will join the Nasdaq-100 effective October 9, replacing Warner Bros. Discovery, adding another biotech name to the index Amgen already calls home.
Amgen (NASDAQ:AMGN) shares slipped on Friday, October 2, as biotech stocks joined the broader health-care sector in sitting out a tech-led market rally. No company-specific news was found for Amgen. The California-based biotech, known for medicines in areas such as bone health, cardiovascular disease and cancer, finished among the decliners on the Dow Jones Industrial Average, which rose 250.40 points to 51,176.96. Amgen also appeared on the list of the Nasdaq-100's losers.
Health Care Was the Lone Laggard
Ten of the 11 S&P 500 sectors rose on Friday. Health care was the only one to fall, and only barely, but the soft patch was spread across several of the group's big names.
In the Dow, Johnson & Johnson and Merck also finished lower, while UnitedHealth was a rare gainer. On the Nasdaq-100, Alnylam Pharmaceuticals and Gilead Sciences were among the decliners, alongside medical-device makers Intuitive Surgical and DexCom. Drug distributors Cardinal Health, McKesson and Cencora fell in the S&P 500.
No single event was identified behind the weakness. The session was one in which money went back into growth after a weak jobs report, while defensive sectors such as health care lagged. The prior day, Thursday, health care had also lagged while energy led.
The Macro Picture
The September jobs report was the main event of the day. The economy added just 29,000 jobs, well short of the roughly 84,000 expected, and revisions removed 60,000 jobs from July and August. Health care was one of the few sectors still hiring, adding 17,000 positions.
The weak data cut the odds of another Federal Reserve rate hike at the October 27-28 meeting. The Fed raised rates on September 16, its first increase since 2023, after the war with Iran pushed oil prices and Inflation higher.
Fed officials have kept up their warnings on prices. Boston Fed President Susan Collins said inflation has been too high for too long, while New York Fed President John Williams said on Thursday there was no need for urgency. Those mixed signals leave investors guessing about the path of borrowing costs, which shapes how they value drugmakers whose payoffs often lie years in the future.
Technology stocks led the rally. The Nasdaq-100 closed at a record 30,807.93, up 306.37 points, and Nvidia hit a record high during the session.
Bond yields complicated the picture. Treasury yields fell right after the report, then reversed to close higher, with the 10-year finishing near its highest level since 2002.
A Biotech Newcomer to the Index
One notable health-care headline came from the index world. Nasdaq announced that Moderna will join the Nasdaq-100 effective October 9, replacing Warner Bros. Discovery. Moderna's shares have rallied strongly since mid-August on cancer-related data, although Citi analyst Geoff Meacham has a Sell rating on the stock.
That change will add another biotech name to the index Amgen already calls home, potentially drawing more investor attention to the group.
Moderna's Index Entry Is the Nearest Catalyst
Moderna's entry into the Nasdaq-100 on October 9 is the nearest index event for the biotech group. Third-quarter Earnings season starts with PepsiCo on October 8 and Delta on October 9, then the big banks on October 13 and 14. The Federal Reserve's October 27-28 meeting is the next key test for the market. If rate fears keep easing, investors may continue to favour high-growth sectors over defensive ones, a trend that weighed on health care on Friday.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...